Published in final edited form as:

Curr Diab Rep. ; 18(5): 28. doi:10.1007/s11892-018-0991-7.

Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes

Scott C. Thomson^{1,2} and Volker Vallon^{1,2}

¹University of California, 3350 La Jolla Village Drive 9151, San Diego, CA 92161, USA

²VA San Diego Healthcare System, San Diego, USA

Abstract

Purpose of Review—The purpose of this review is to correlate predictions based on pre-clinical data with outcomes from clinical trials that examine the effects of incretin-based diabetes treatments on the kidney. The incretin-based treatments include agonists of the glucagon-like peptide 1 receptor (GLP-1R) and inhibitors of the enzyme, dipeptidyl peptidase-4 (DPP-4). In addition, what is known about the incretin-based therapies will be compared to what is known about the renal effects of SGLT2 inhibitors.

Recent Findings—Large-scale clinical trials have shown that SGLT2 inhibitors reduce albuminuria and preserve estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy. A concise and plausible hemodynamic mechanism is supported by pre-clinical research on the physiology and pharmacology of SGLT2. Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria but have not shown beneficial effects on eGFR. Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s). But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.

Summary—There may be salutary effects of incretin-based treatments on the diabetic kidney, but the system is complex and not amenable to simple explanation or prior prediction. This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.

Keywords

DPP-4; GLP-1; SGLT2; Glomerular filtration; Tubular reabsorption; Albuminuria

Scott C. Thomson sthompson@ucsd.edu.

Compliance with Ethical Standards

Conflict of Interest Dr. Thomson has received research support from Merck and Pfizer. Dr. Vallon has served as a consultant and received honoraria from Boehringer Ingelheim, Intarcia Therapeutics, Janssen Pharmaceutical, Eli Lilly, and Merck, and received grant support for investigator-initiated research from Boehringer Ingelheim, Astra-Zeneca, Fresenius, Janssen, and Bayer.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Introduction

At the onset of diabetes, the kidney grows large and GFR becomes supranormal [1–3]. This early growth and hyperfunction appear to be most pronounced in the subset of patients with diabetes who proceed to develop diabetic nephropathy many years later [1, 4–9]. Current treatment for diabetic nephropathy is centered on blocking the renin-angiotensin-aldosterone system (RAAS) and is palliative. Treatment that reduces the actual incidence of diabetic nephropathy while reducing the pill burden on patients with diabetes would be preferable. Hence, it is worthwhile to consider whether a particular regimen aimed at glycemic control in diabetes might also exert “off target” effects on the kidney that forestall the onset of diabetic nephropathy or slow its progression. This consideration has gained attention during the development of sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based drugs for lowering blood glucose. We will discuss some of the clinical and pre-clinical data pertaining to this subject. Our principal charge is to discuss the current state of knowledge about incretin-based therapies. We will put this in context by making comparison to the current understanding of SGLT2.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, and tofogliflozin) lower blood glucose levels by blocking reabsorption of most filtered glucose by the proximal tubule [10]. In the course of preventing glucose uptake by the early proximal tubule, acute SGLT2 blockade inevitably shifts the burden for reabsorbing a greater fraction of the filtered sodium chloride (NaCl) and fluid to later segments of the nephron and elicits a tubuloglomerular feedback (TGF) response, which suppresses hyperfiltration. These immediate effects on tubular and glomerular function have been validated in micropuncture experiments [11–12]. It has now been shown that the effect is durable and, thus, sufficient to explain the persistent, yet rapidly reversible, suppression of hyperfiltration by SGLT2 blockers in human subjects [12–15]. SGLT2 blockers likely have other effects on the kidney that will come to light through ongoing research, but this concise framework suffices to explain the main effects on renal salt handling and hemodynamics.

Incretin-based therapies have more complicated renal mechanisms of action than SGLT2 blockade. Incretin-based therapies include glucagon-like peptide-1 receptor (GLP-1R) agonists (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide), which activate GLP-1R directly, and dipeptidyl peptidase-4 (DPP-4) inhibitors (linagliptin, saxagliptin, sitagliptin, vildagliptin), which impede the degradation of endogenous GLP-1. The useful GLP-1R agonists are resistant to DPP-4. Incretin-based treatments lower blood glucose by a combination of effects that follow activation of GLP-1R at various sites. The mechanism of glucose lowering by incretin-based drugs is more complex than that for SGLT2 blockade, but it has been defined [16]. The effects of GLP-1R agonists and DPP-4 inhibitors on basic kidney function(s) are more complex than those of SGLT2 inhibitors, and they are less well-defined.

A predictive model for effects of incretin-based treatments on the kidney will be inherently more difficult to develop than a predictive model for SGLT2, because it must include more variables. SGLT2 is confirmed to exist only in the early proximal tubule, which naturally puts sodium and glucose transport in the early proximal tubule at the hub of any model of its

actions. But GLP-1R and DPP-4 are expressed throughout the body [17, 18]. Furthermore, GLP-1 fragments may be bioactive at sites other than GLP-1R while DPP-4 has many substrates other than GLP-1 with potential to impinge on the kidney through different signaling pathways [19, 20, 21]. Thus, a GLP-1R agonist or DPP-4 inhibitor may simultaneously alter the activity of multiple effectors that compete for control of a given variable. This will make the net effect of a GLP-1R agonist or DPP-4 inhibitor on that variable strongly dependent on the physiological or experimental conditions in ways that may not be obvious.

Incretins in Renal Hemodynamics and Tubular Reabsorption

To fully characterize the tonic influence of GLP-1R activity in kidney, physiology would require a potent pharmacologic GLP-1R antagonist, which does not exist, although experiments with a weak GLP-1R antagonist, exendin-(9–39), were able to establish that GLP-1 is a natriuretic factor [22]. Acute infusion of GLP-1R agonist, exenatide, causes selective renal vasodilation and diuresis in rats and wild-type mice, but not in GLP-1R knockout mice, thus conferring specificity of the agonist to GLP-1R [23, 24]. The proximal tubule contains GLP-1R and DPP-4, which presumably degrades filtered GLP-1. Intravenous exenatide acutely suppressed proximal reabsorption in micropuncture experiments, which were designed to distinguish primary effects of exenatide on proximal reabsorption from effects mediated by changes in filtered load [23]. Exenatide also suppresses proximal reabsorption when applied directly into Bowman's space by microperfusion, confirming a role for tubular GLP-1R (unpublished). GLP-1R activation has been associated with PKA-mediated phosphorylation and potential inactivation of sodium-hydrogen exchanger 3 (NHE3) in the proximal tubule, providing a plausible mechanism for the diuretic effect [24–26].

Increases in GFR and urine output during acute exenatide infusion in rats are abrogated when systemic nitric oxide activity is clamped with a mixture of a generalized NOS inhibitor and sodium nitroprusside [27]. Analogous renal responses to acute exenatide infusion were recently reported for human subjects with and without type 2 diabetes. For example, exenatide caused nitric oxide-dependent renal vasodilation in overweight humans and reduced proximal reabsorption in humans with type 2 diabetes [28•, 29•]. The natural response to an isolated reduction in proximal reabsorption is to activate TGF and reduce GFR. For exenatide to simultaneously suppress proximal reabsorption and increase GFR, it must have an additional vascular effect to override the activation of TGF. The differential effect on humans with and without diabetes in these two recent studies could be explained if the tubular effects were to dominate the vascular effect in patients with diabetes and vice versa in patients without diabetes. This would be consistent with the overall tendency in diabetes for the proximal tubule to become the dominant controller of GFR [30–31].

Any chronic effect of GLP-1R agonist on renal function is expected to be of lesser magnitude than what is observed with acute infusion. The counter-regulatory processes that engage to mitigate the primary response to GLP-1R agonist are pertinent to predicting what role GLP-1R agonists might play in long-term renal protection. This is a subject of ongoing investigation. In humans with type 2 diabetes, there is a class effect of GLP-1R agonists to

reduce long-term blood pressure [32]. According the Guyton principle, this implies that GLP-1R agonists either reduce sodium intake or reduce the level of blood pressure required by the kidney to excrete the daily sodium intake [33].

The renal response to DPP-4 inhibitors is more subtle and complicated than the response to GLP-1R agonists. DPP-4 inhibitors suppress NHE3 activity in the OKP line of opossum kidney proximal tubule cells, suggesting these drugs should suppress proximal reabsorption by a mechanism linked to a tyrosine kinase [34]. Indeed, systemic administration of DPP-4 inhibitors does modestly reduce proximal reabsorption in mice. However, this effect persists in mice lacking GLP-1R and does not involve phosphorylation of NHE3 [24]. Preliminary micropuncture experiments from our lab have shown that acute intravenous DPP-4 inhibition causes a slight decrease in proximal reabsorption in the rat, as others suggest should happen. But contrary to expectation, direct microperfusion of the same DPP-4 inhibitor to the neck of Bowman's space, i.e., directly into the early proximal tubule, causes a major increase in fluid reabsorption (unpublished). Thus, there are studies in mice and micropuncture data from rats that are incompatible with the current model whereby DPP-4 inhibitors act as proximal tubular diuretics by direct action on DPP-4 in the proximal tubule to affect the phosphorylation state of NHE3. Acute vasodilatory effects of DPP-4 inhibitors in other organs are also independent of GLP-1R activation [35]. Hence, effects of DPP-4 inhibitors on salt, fluid, and blood pressure homeostasis will be more complex, variable, and difficult to explain than the effects of GLP-1R agonists. Proposed mechanisms to explain effects of DPP-4 inhibitors on albuminuria and how they could mitigate kidney injury are reviewed elsewhere in detail [36].

Renal Outcomes in Large-scale CVD Safety Trials in Patients With Type 2 Diabetes

Since 2008, the Food and Drug Administration has required new glucose-lowering therapies be proven safe from a cardiovascular standpoint [37]. This was the era when SGLT2 and incretin-based diabetes treatments were being developed. Hence, there are rigorously obtained data from large-scale clinical trials designed to measure cardiovascular disease (CVD) outcomes in patients with diabetes randomized to receive SGLT2 inhibitors and incretin-based treatments. Investigators who designed these trials all faced the same stipulation, which was to prove non-inferiority of a novel agent with respect to CVD outcomes. Hence, several of the studies are comparable in their basic design for assessing and reporting CVD outcomes of different drugs, and their findings are fairly amenable to comparison, albeit some differences in the pharmacology of particular agents or study populations have been cited.

While it was the primary objective of these trials to confirm CVD safety, some also acquired data on microvascular complications, including diabetic kidney disease, and reported these as secondary outcomes, either in the primary publication or in follow-up publications. Most reports on renal outcomes with incretin-based drugs only cite statistics on a composite renal outcome that combines some measure of albuminuria, declining estimated glomerular filtration rate (eGFR), and incident end-stage renal disease (ESRD). But while declining GFR and incident ESRD are included in the composite renal outcome, the data from these trials lack a clear signal for declining kidney function and the composite in the clinical trials

of incretin-based treatments is driven by effects on albuminuria. In contrast to the incretin-based CVD trials, the major SGLT2 trials were able to demonstrate a salutary effect on long-term GFR and report this separately from the composite renal outcome [38–39]. Prima facie, this suggests that SGLT2 blockade is more effective at mitigating loss of kidney function than are incretin-based therapies. SGLT-2 also has the advantage of a concise and plausible hemodynamic justification for improved renal outcomes, which is analogous to the original explanation given for the renal benefit of RAAS blockade [9]. The main renal outcomes of these trials are shown in Table 1.

A caveat is that the placebo-treated groups in the incretin-based trials suffered fewer declines in eGFR than their counterparts in SGLT2 trials so there was less for the incretin-based treatments to improve upon. This also applies to a pooled analysis of renal disease endpoints from 13 large randomized linagliptin trials, which found a renal benefit in terms of reduced albuminuria, but lacked the power to detect effects on eGFR [40•]. Results from individual trials that reported renal endpoints are as follows:

Individual Trials of GLP-1R Agonists

SUSTAIN-6 (GLP-1R Agonist Trial): [ClinicalTrials.gov Number, NCT01720446](#) This study examined the effect of GLP1-R agonist, semaglutide, on cardiovascular disease (CVD) out-comes. There were fewer CVD events in subjects receiving semaglutide vs. placebo (6.6 vs. 8.9%, hazard ratio 95% confidence interval (CI) 0.58 to 0.95; $P < 0.001$ for non-inferiority; $P = 0.02$ for superiority). New or worsening nephropathy was less in those treated with semaglutide vs. placebo (3.8 vs. 6.1%, hazard ratio CI 0.46–0.88, $P = 0.005$) as defined by macroalbuminuria or doubling of the serum creatinine level to eGFR less than 45 ml per minute. The determinative factor was albuminuria [41•].

LEADER (GLP-1R Agonist Trial): [ClinicalTrials.gov Number, NCT01179048](#) This study examined the effect of GLP-1R agonist, liraglutide, on CVD outcomes. There were fewer CVD events in subjects receiving liraglutide than placebo (13.0 vs. 14.9%, hazard ratio CI 0.87–9.97, $P < 0.001$ for non-inferiority, $P < 0.01$ for superiority) [42]. New or worsening nephropathy was less with liraglutide (5.7 vs. 7.2%, hazard ratio CI 0.67–0.92, $P = 0.003$). Again, the improved renal outcomes were driven by lower incidence of albuminuria rather than loss of kidney function [43•].

Trials of DPP-4 Inhibitors

SAVOR-TIMI 53 (DPP-4 Inhibitor Trial): [ClinicalTrials.gov Number, NCT01107886](#) This study examined the effect of DPP-4 antagonist, saxagliptin, on CVD outcomes. Saxagliptin had no effect on the rate of ischemic events but increased the incidence of hospital admissions for congestive heart failure by 25% (3.5 vs. 2.8%; hazard ratio CI 1.07 to 1.51; $P = 0.007$). Participants treated with saxagliptin were more likely to have an improved albumin to creatinine ratio and less likely to have a worsening ratio ($P < 0.001$). The full effect on albuminuria was manifest within the first year of treatment, so it was likely functional. Approximately 2% of participants experienced doubling of creatinine, reached plasma creatinine concentrations > 6 mg/dl, or required renal replacement therapy in

the course of the trial, and these outcomes were not affected by saxagliptin (hazard ratio CI 0.88–1.32, $P = 0.46$) [44•].

TECOS (DPP-4 Inhibitor Trial): [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00790205) Number NCT00790205 This study showed that sitagliptin was noninferior to usual care with respect to CVD outcomes in participants with established CVD [45]. Ancillary data included repeated measures of eGFR, which remained stable over the 4-year study in both treatment groups and among those entering the trial with stage 3 chronic kidney disease (CKD) or normal kidney function. Albuminuria was not addressed [46•].

In a meta-analysis of 13 smaller randomized trials including ~4500 subjects, treatment with DPP-4 inhibitor, linagliptin, was associated with less new onset moderate albuminuria, but there were too few instances of CKD progression to draw conclusions about long-term effect on kidney function or kidney survival [40•].

While renal outcomes were ancillary in the foregoing CVD trials, we are aware of one published randomized DPP-4 inhibitor trial designed primarily to look at renal outcomes. This trial (MARLINA-T2D study, [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01792518), NCT01792518) was designed to investigate the renal effects of linagliptin in individuals with type 2 diabetes and preexisting albuminuria on RAAS blockade. After 24 weeks, linagliptin had no effect on eGFR or albuminuria. The authors were left to speculate as to why this dedicated study failed to fulfill expectations of reduced albuminuria based on large amounts of data from the earlier CVD trials [47•].

To summarize, using changes in albuminuria as a surrogate for renal disease, most, but not all, data from large randomized clinical trials point toward reduced albuminuria with incretin-based therapies, which may be an intermediate phenotype for renal preservation. In contrast, clinical trial data obtained with SGLT2 inhibitors also show preserved kidney function.

Alternative Mechanisms for Salutary Renal Effects of DPP-4 Inhibitors

Since DPP-4 has many substrates, effects of DPP-4 inhibitors are expected to be pleiotropic, and several investigators have mined these for effects that might be useful. Pre-clinical studies ascribe several properties to DPP-4 inhibitors that could be conceived as beneficial. Among these, DPP-4 inhibitors have been described as anti-fibrotic, anti-oxidant, anti-apoptotic, and anti-inflammatory [48–57]. These arguments are plausible and include molecular detail. One would imagine, given a list of potential effects this open-ended, that biological effects of DPP-4 inhibitors, once discovered, would distribute randomly between categories currently viewed as “good” and “bad.” However, those findings that are published provide only optimism for the future of DPP-4 inhibitors in CKD and suggest no pitfalls. But similar properties have been imputed to dozens of other xenobiotics over the years, none of which has translated to effective treatment for human CKD. The track record of other proposed CKD treatments for which similar claims were initially made and the outcomes from randomized clinical trials with DPP-4 inhibitors militate circumspection.

Conclusions

Progress is being made through both basic science and clinical trials to establish the proper role for SGLT2 inhibitors and incretin-based therapies in human diabetes where they may improve cardiovascular and renal outcomes. At this point, the SGLT2 inhibitors enjoy an edge over incretin-based therapies with respect to renal outcomes inasmuch as SGLT2 inhibitors were clearly shown to slow the decline in eGFR in two out of two large-scale clinical trials while incretin-based drugs failed to do so in any of four similarly designed trials (see Table 1). SGLT2 inhibitors also enjoy an advantage of better coherence between the basic science and the clinical trial results. One reason for this is that the incretin-based therapies impinge on numerous factors at once, which makes their emergent properties difficult to predict.

Acknowledgments

Funding The authors work was supported by the National Institutes of Health (R01DK56248, R01DK112042, R01DK106102, P30DK079337), the Department of Veterans Affairs, and investigator-initiated research grants by Bristol-Myers Squibb, Merck, and Boehringer Ingelheim.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. *Annu Rev Physiol.* 2015;74:351–75.
2. Mogensen CE. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. *Scand J Clin Lab Invest.* 1971; 28:91–100. [PubMed: 5093523]
3. Melsom T, Mathisen UD, Ingebretsen OC, Jenssen TG, Njolstad I, Solbu MD, et al. Impaired fasting glucose is associated with renal hyperfiltration in the general population. *Diabetes Care.* 2011;34: 1546–51. [PubMed: 21593291]
4. Mogensen CE. Early glomerular hyperfiltration in insulin-independent diabetics and late nephropathy. *Scand J Clin Lab Invest.* 1986;46:201–6. [PubMed: 3715374]
5. Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. *Diabetes Care.* 2012;35:2061–8. [PubMed: 22773704]
6. Moriya T, Tsuchiya A, Okizaki S, Hayashi A, Tanaka K, Shichiri M. Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes. *Kidney Int.* 2012;81:486–93. [PubMed: 22157655]
7. Silveiro SP, Friedman R, de Azevedo MJ, Canani LH, Gross JL. Five-year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. *Diabetes Care.* 1996;19:171–4. [PubMed: 8718441]
8. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. *Diabetologia.* 2009;52:691–7. [PubMed: 19198800]
9. O'Bryan GT, Hostetter TH. The renal hemodynamic basis of diabetic nephropathy *Semin Nephrol.* 1997;17:93–100. [PubMed: 9148381]
10. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. *J Am Soc Nephrol.* 2011;22:104–12. [PubMed: 20616166]

11. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. *J Am Soc Nephrol.* 1999;10: 2569–76. [PubMed: 10589696]
12. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. *Am J Physiol Regul Integr Comp Physiol.* 2012;302:R75–83. [PubMed: 21940401]
13. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation.* 2014;129:587–97. [PubMed: 24334175]
14. Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol.* 2016;29:391–400. [PubMed: 26894924]
15. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med* 2016; 375:323–334. [PubMed: 27299675]
16. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. *Pharmacol Rev.* 2008;60:470–512. [PubMed: 19074620]
17. Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody *Endocrinology.* 2014;2014(155):1280–90.
18. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. *Endocr Rev.* 2012;33:187–215.
19. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocr Rev.* 2014;35:992–1019.
20. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Circulation.* 2017;136:849–70. [PubMed: 28847797]
21. Dipeptidyl-peptidase Mentlein R., IV (CD26)-role in the inactivation of regulatory peptides. *Regul Pept.* 1999;85(1):9–24. [PubMed: 10588446]
22. Farah LX, Valentini V, Pessoa TD, Malnic G, McDonough AA, Girardi AC. The physiological role of glucagon-like peptide-1 in the regulation of renal function. *Am J Physiol Renal Physiol.* 2016;310:F123–7. [PubMed: 26447224]
23. Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. *Am J Physiol Renal Physiol.* 2013;304:F137–44. [PubMed: 23019232]
24. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. *Am J Physiol Renal Physiol.* 2012;303:F963–71. [PubMed: 22832924]
25. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. *Am J Physiol Renal Physiol.* 2011;301:F355–63. [PubMed: 21593184]
26. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. *Regul Pept.* 2007;141:120–8. [PubMed: 17276524]
27. Thomson SC, Kashkouli A, Liu ZZ, Singh P. Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin. *Am J Physiol Renal Physiol.* 2017;313:F854–8. [PubMed: 28724607]
28. Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA, et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. *Diabetes Obes Metab.* 2016; 18:178–85. [PubMed: 26636423] •Study showing acute renal vasodilation in response to acute GLP-1R agonist in non-diabetic humans. Findings are analogous to earlier animal studies (ref. 23).
29. Tonneijck L, Smits MM, MHA M, Hoekstra T, Kramer MHH, Danser AHJ, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a

- randomised, double-blind, placebo-controlled trial. *Diabetologia*. 2016; 59: 1412–21. [PubMed: 27038451] •Study from same laboratory as ref. 28 showing acute decline in proximal reabsorption but no renal vasodilation in response to acute GLP-1R agonist in diabetic humans. Putative explanation for lack of renal vasodilation in diabetics is that the tubular effect led to activation of TGF to offset the direct vasodilatory response seen in ref. 28.
30. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. *Am J Physiol Renal Physiol*. 2004;286:F8–15. [PubMed: 14656757]
 31. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. *AnnuRev Physiol*. 2012;74:351–75.
 32. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. *J Diabetes Complicat*. 2014;28:399–405. [PubMed: 24561125]
 33. Guyton AC, Lohmeier TE, Hall JE, Smith MJ, Kastner PR. The infinite gain principle for arterial pressure control by the kidney- volume-pressure system In: Sambhi MP, editor. *Fundamental fault in hypertension*. Developments in cardiovascular medicine. Dordrecht: Springer; 1984 p. 36.
 34. Girardi AC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Na⁺/H⁺ exchanger isoform NHE3 in proximal tubule cells. *Am J Physiol Cell Physiol*. 2004;287:C1238–45. [PubMed: 15213057]
 35. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, ... & Villamena F Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. *Vasc Pharmacol* 2011;55: 2–9.
 36. Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. *Am J Physiol Renal Physiol*. 2017;312:F661–70. [PubMed: 28122713]
 37. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, 12 2008 <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf>.
 38. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375:323–34. [PubMed: 27299675]
 39. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erond N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017; 377:644–657. [PubMed: 28605608]
 40. Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, et al. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. *Am J Kidney Dis*. 2015;66:441–9. [PubMed: 25960304] •Patient- level data from combined linagliptin trials showing DPP-4 treatment improves a composite renal endpoint. It was not mentioned in the abstract that the result was driven by lower incident albuminuria, not by preservation of eGFR.
 41. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016; 375:1834–44. [PubMed: 27633186] •CVD outcome trial with GLP-1R agonist showing lower incidence of albuminuria, but lacking power to study impact on renal function.
 42. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–22. [PubMed: 27295427]
 43. Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med*. 2017; 377:839–48. [PubMed: 28854085] •Secondary publication from CVD trial of another GLP-1R agonist showing lower incidence of albuminuria, but lacking power to study impact on renal function.
 44. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013; 369: 1317–26. [PubMed: 23992601] •CVD trial of DPP-4 inhibitor, saxagliptin, reporting salutary effect on proteinuria but no impact on eGFR.

45. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373:232–42. [PubMed: 26052984]
46. Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, et al. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. *Diabetes Obes Metab*. 2017, 19:1587–93. [PubMed: 28432745] •Ancillary data from CVD trial of DPP-4 inhibitor, sitagliptin, showing no effect on eGFR over 4-year period. However, the rate of decline in eGFR in both treatment and placebo groups was negligible.
47. Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. *Diabetes Obes Metab*. 2017, 19:1610, 1619. [PubMed: 28636754] •Only randomized DPP-4 inhibitor trial designed with primary renal endpoint. In this trial, linagliptin had no effect on albuminuria or eGFR.
48. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial- to-mesenchymal transition in a therapeutic regimen. *Diabetes*. 2014;63:2120–31. [PubMed: 24574044]
49. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to- mesenchymal transition. *Kidney Int*. 2015;88:479–89. [PubMed: 25830763]
50. Takashima S, Fujita H, Fujishima H, Shimizu T, Sato T, Morii T, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. *Kidney Int*. 2016;90:783–96. [PubMed: 27475229]
51. Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. *J Hypertens*. 2013;31:2290–9. [PubMed: 24077249]
52. Nistala R, Habibi J, Aroor A, Sowers JR, Hayden MR, Meuth A, et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat. *Obesity*. 2014;22:2172–9. [PubMed: 24995775]
53. Zhuge F, Ni Y, Nagashimada M, Nagata N, Xu L, Mukaida N, et al. DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. *Diabetes*. 2016;65:2966–79. [PubMed: 27445264]
54. Uchii M, Kimoto N, Sakai M, Kitayama T, Kunori S. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats. *Eur J Pharmacol*. 2016;15(783):56–63.
55. Alam MA, Chowdhury MRH, Jain P, Sagor MAT, Reza HM. DPP- 4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. *Diabetol Metab Syndr*. 2015;7:107. [PubMed: 26609328]
56. Zeisberg M, Zeisberg EM. Evidence for antifibrotic incretin- independent effects of the DPP-4 inhibitor linagliptin. *Kidney Int*. 2015;88:429–31. [PubMed: 26323066]
57. Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. *Am J Physiol Renal Physiol*. 2015;308:F878–87. [PubMed: 25656369]

Table 1

Study characteristics and renal outcomes in major clinical trials of incretin-based and SGLT2 inhibitor drugs

Trial	Agent	Sample size Median time of follow-up Baseline participant characteristics	Renal endpoints	Result	P value
Sustain-6 [41•]	GLP1-R agonist	<i>n</i> = 3297	Incident albuminuria *	2.7 vs. 4.9%	0.001
	Semaglutide	25 months ~ 60% CVD ~ 25% eGFR < 60	Decline in eGFR *	1.1 vs. 0.8%	ns
LEADER [43•]	GLP1-R agonist	<i>n</i> = 9340	Incident albuminuria *	3.4 vs. 4.6%	0.004
	Liraglutide	46 months ~ 81% CVD ~ 25% eGFR < 60	Decline in eGFR *	1.8 vs. 2.1%	ns
SAVOR-TIMI 53 [44•]	DPP-4 inhibitor	<i>n</i> = 12,360	Increased albuminuria *	13 vs. 16%	0.001
	Saxagliptin	25 months ~ 78% CVD ~ 16% eGFR < 50	Decline in eGFR *	2.2 vs. 2.0%	ns
TECOS [46•]	DPP-4 inhibitor	<i>n</i> = 14,671	Urine albumin/creatinine (mg/g)	11.1 vs. 10.9	0.03
	Sitagliptin	36 months ~ 75% CVD 23% eGFR < 60	Rate of decline in eGFR (ml/min/year)	1.0 vs. 0.7	ns
EMPA-REG OUTCOME [15]	SGLT2 blocker	<i>n</i> = 7020	Incident albuminuria *	11 vs. 16%	<0.001
	Empagliflozin	37 months ~ 80% CVD ~ 26% eGFR < 60	Decline in eGFR *	1.5 vs. 2.6%	<0.001
CANVAS [39]	SGLT2 blocker	<i>n</i> = 10,142	Incident albuminuria **	9 vs. 13	<0.001 ****
	Canagliflozin	47 months ~ 66% CVD ~ 25% eGFR < 60 ***	> 40% decline in eGFR **	0.5 vs. 0.9	<0.001 ****

CVD cardiovascular disease, eGFR estimated glomerular filtration rate

* > 300 mg albumin/g creatinine or halving of eGFR to < 45 ml/min/1.73 m² during course of trial

** Events per 100 pt-years

*** Inferred from mean (SD) eGFR assuming normal distribution

**** Computed from 95% confidence intervals